Hypera (HYPE3.SA) Azione Prezzo
Hypera Prezzo
Negli ultimi 19 anni Hypera ha aumentato il fatturato del 17,2% all'anno, raggiungendo 7,70 miliardi BRL. L'utile per azione è cresciuto del 15,8% all'anno negli ultimi 18 anni. Per Hypera, il margine netto del 15,5% risulta in calo rispetto al 22,4% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 4,35%. Il payout ratio è pari a circa il 63% degli utili. Il dividendo è cresciuto del 17,6% all'anno negli ultimi 14 anni. Il target di prezzo di consenso a 12 mesi per Hypera è 30,09 BRL, circa il 11,9% sopra il prezzo attuale di mercato. Su 19 analisti, 13 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Hypera Prezzo delle azioni
Hypera Azione e analisi azionaria
Domande frequenti sull'azione Hypera
Hypera SA, a leading pharmaceutical company based in Brazil, operates on a robust business model. The core of their business involves the manufacturing, marketing, and distribution of a wide range of pharmaceutical products. Hypera SA specializes in both prescription and over-the-counter medications, catering to various therapeutic areas. They also produce medical-hospital products and non-pharmaceutical items such as personal hygiene and beauty care products. With a focus on innovation and quality, Hypera SA aims to improve the health and well-being of individuals across the country. As a prominent player in the pharmaceutical industry, Hypera SA continues to expand its product portfolio, enhance operational efficiency, and ensure customer satisfaction.
Hypera SA is primarily active in the pharmaceutical industry.
The main competitors of Hypera SA in the market are pharmaceutical companies such as Aché Laboratórios, EMS Pharma, and Eurofarma.
Hypera SA, formerly known as Hypermarcas SA, is a leading pharmaceutical company based in Brazil. Founded in 2001, Hypera has a rich history and has significantly grown over the years. It focuses on the development, production, and commercialization of pharmaceutical products, generic drugs, over-the-counter medications, and personal care items. Hypera has established a strong presence in the Brazilian market, offering a wide range of high-quality and affordable healthcare solutions. Its commitment to research and innovation has led to numerous successful product launches. Hypera SA continues to be a prominent player in the pharmaceutical industry, continuously expanding its portfolio and enhancing the well-being of consumers.
Hypera SA, a renowned company in the pharmaceutical industry, has accomplished several significant milestones throughout its journey. The company has successfully positioned itself as a leader in the Latin American market, expanding its presence across various countries. Hypera SA has consistently demonstrated its commitment to innovation and research, introducing numerous breakthrough pharmaceutical products. With strategic acquisitions and partnerships, the company has further strengthened its portfolio and market share. Hypera SA's relentless focus on quality control and strict adherence to regulatory standards has earned it a stellar reputation among industry experts and stakeholders. These achievements reflect Hypera SA's dedication to advancing healthcare solutions and driving long-term growth in the pharmaceutical sector.
Hypera SA is primarily present in Brazil.
Hypera SA represents a strong commitment to its corporate philosophy, which revolves around innovation, excellence, and integrity. With a focus on enhancing quality of life, Hypera SA aims to deliver innovative healthcare solutions to consumers. The company puts a strong emphasis on research and development, constantly striving to introduce new and effective products to market. By promoting a culture of excellence, Hypera SA seeks to provide top-notch customer service and quality-assured products. With a dedication to integrity, the company operates transparently and ethically, ensuring trust and reliability among its stakeholders. Hypera SA's values and corporate philosophy ultimately drive its mission to positively impact people's health and well-being.
Gli analisti fissano attualmente un prezzo obiettivo medio di 30,54 BRL per l’azione Hypera (mediana: 30,09 BRL), pari a +13,6 % rispetto all’ultimo prezzo. Il consenso si basa su 19 giudizi di analisti.
19 analisti valutano attualmente l’azione Hypera: 13 raccomandano l’acquisto, 6 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Hypera ricavi pari a 9,25 miliardi BRL e un utile per azione di 2,62 BRL.
Convertita al tasso di cambio attuale, l’azione Hypera quota 4,79 EUR (26,89 BRL).
L’azione Hypera (HYPE3.SA) è quotata su 2 borse, tra cui: B3 (São Paulo) (HYPE3.SA).
The Brazilian company Hypera SA is a leading manufacturer and distributor of pharmaceuticals, dietary supplements, cosmetics, and household products. It has been listed on the stock exchange since 2008 and has built a strong presence in the Brazilian market in recent years. Hypera SA operates in four business segments: Consumer Health, Pharma, Over-the-Counter medicines, and Cosmetics and Skincare products. The Consumer Health division offers a wide range of products such as vitamins, pain relievers, cough and cold medicines, as well as dietary supplements and baby food. Hypera SA's Pharma business includes prescription drugs, including medications for cardiovascular, diabetes, gastroenterology, and oncology patients. Additionally, the company also provides vaccines and medications for respiratory diseases. In the Over-the-Counter medicines segment, the company offers a wide range of non-prescription medications for colds, digestive issues, pain, and allergies. This includes diet and weight loss products, vitamins and minerals, as well as other supplements. Hypera SA also offers a variety of cosmetic and skincare products, including brands like Episol, Hair Fly, Monange, Neostrata, and Assolan. The company also operates a household products division, which includes brands like Vitasay, Tixan, and Blergh. The product range of Hypera SA is diverse, ranging from affordable mass-market products to more expensive premium brands. The company aims to reach a wide range of customers and has specialized in marketing products for the health and beauty segment. It has established relationships with major retail chains as well as pharmacies and other sales locations. Hypera SA strives to integrate innovation and technology into its business model. The company has a research and development team constantly developing and launching new products. It also invests in automation and digitization of its production facilities to improve the efficiency and quality of its products. Overall, Hypera SA's business model is focused on a wide product range and a strong brand presence. The company relies on price competition and innovation to strengthen its market position. As a leading provider of healthcare, cosmetic, and household products in Brazil, the company aims to expand internationally.
Il attesa fatturato di Hypera ammonta a 9,25 miliardi BRL. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Hypera ammonta a 1,68 miliardi BRL. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Hypera è attualmente 10,28. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Hypera.
Il rapporto prezzo/fatturato (P/S) di Hypera è attualmente 1,87. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Hypera.
Il Quality Score AlleAktien per Hypera è 6/10.
L'ISIN di Hypera è BRHYPEACNOR0. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di Hypera è HYPE3.SA. Con questo simbolo di borsa vengono negoziate le azioni Hypera in borsa.
Azione Hypera
Altre metriche e analisi di Hypera in Deep Dive.
La nostra analisi azionaria dell'azione Hypera include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Hypera. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: